Download the 2025 mRNA Drug Development Presentation
Why This mRNA Drug Development Data Is Essential
This presentation is your competitive advantage. Here’s what you’ll gain access to:
Preclinical Pipeline & Up-to-Date Clinical Trial Intelligence
- 560+ RNA-focused biopharma companies are active but not yet in clinical phases — a massive opportunity pool.
- The number of mRNA cancer vaccine trials initiated each year steadily increased, with a CAGR of 42% since 2020.
- 88% of mRNA therapies are still in preclinical or early-stage clinical phases, offering key partnership opportunities.
Global mRNA Regulatory Insights
- 30% of all RNA regulatory announcements from January to July 2025 were mRNA-related.
- Learn how shifts in the global regulatory environment are accelerating mRNA trial approvals and shaping market access strategies.
mRNA Deal-Making and Investment Trends
- $5 billion in total deal value and $2 billion in upfront cash were generated in H1 2025 alone.
- Since 2020, 57% of mRNA-centred collaboration deals focus on the development of platform technologies for new applications in drug development.
- Financing trends show a pivot toward fewer but higher-value investments in clinically validated platforms.
You May Also Be Interested In…
Learn More About RNA
- The Most Comprehensive Way to Search the RNA Drug Development Landscape: Unique search ontologies based on RNA drug and trial characteristics
- Market Leading Approach to RNA Preclinical & Clinical Data Curation: Manual curation of key RNA research and development data points by RNA research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search RNA company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
